Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00371345
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 92
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Study completedNCT00458237
What this trial is testing

Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Beth Israel Deaconess Medical Center 11
Testing effectiveness (Phase 2)Study completedNCT02648477
What this trial is testing

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
City of Hope Medical Center 30
Testing effectiveness (Phase 2)UnknownNCT04963595
What this trial is testing

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Zhiyong Yu 100
Testing effectiveness (Phase 2)UnknownNCT04033172
What this trial is testing

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Chinese Academy of Medical Sciences 40
Not applicableStudy completedNCT04916509
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Who this might be right for
Breast Neoplasms
Pfizer 258
Large-scale testing (Phase 3)Not Yet RecruitingNCT07340658
What this trial is testing

Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Rovi Pharmaceuticals Laboratories 300
Testing effectiveness (Phase 2)Looking for participantsNCT05523947
What this trial is testing

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Who this might be right for
HER2-Positive Solid Tumor
Yuhan Corporation 147
Early research (Phase 1)Study completedNCT03650348
What this trial is testing

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 41
Large-scale testing (Phase 3)UnknownNCT04924699
What this trial is testing

MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
Shanghai Miracogen Inc. 350
Large-scale testing (Phase 3)Active Not RecruitingNCT03975647
What this trial is testing

Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 466
Testing effectiveness (Phase 2)Ended earlyNCT01702558
What this trial is testing

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Who this might be right for
Breast CancerGastric Cancer
Hoffmann-La Roche 182
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07152782
What this trial is testing

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-positive Breast Cancer
Fudan University 202
Testing effectiveness (Phase 2)Looking for participantsNCT05573126
What this trial is testing

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer
Ellipses Pharma 95
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Testing effectiveness (Phase 2)Study completedNCT00777101
What this trial is testing

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerBreast Cancer
Puma Biotechnology, Inc. 233
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Testing effectiveness (Phase 2)Looking for participantsNCT07112053
What this trial is testing

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington 40
Next Page